氯巴占与大麻二酚辅助治疗Lennox-Gastaut综合征新进展  

Advances in the Adjunctive Treatment of Lennox⁃Gastaut Syndrome with Clobazam and Cannabidiol

作　　者：石静天 陈超阳[1] 杨婷[1] 魏然 张玄龄 王梓凝[1] 胡晓娟 周颖[1,2] SHI Jingtian;CHEN Chaoyang;YANG Ting;WEI Ran;ZHANG Xuanling;WANG Zining;HU Xiaojuan;ZHOU Ying(Department of Pharmacy,Peking University First Hospital,Beijing 100034,China;Drug Clinical Trial Facility,Peking University First Hospital,Beijing 100034,China;Department of Pharmacy,Peking University First Hospital Ningxia Women and Children′s Hospital,Ningxia Hui Autonomous Region Maternal and Child Health Hospital,Yinchuan 750001,China)

机构地区：[1]北京大学第一医院药剂科,北京100034 [2]北京大学第一医院药物临床试验机构,北京100034 [3]北京大学第一医院宁夏妇女儿童医院(宁夏回族自治区妇幼保健院)药剂科,银川750001

出　　处：《罕见病研究》2024年第2期252-259,共8页Journal of Rare Diseases

摘　　要：Lennox-Gastaut综合征(LGS)是一种严重的癫痫性脑病。近年来,已有多种药物被批准用于治疗LGS。美国食品药品监督管理局分别于2011年10月和2018年6月批准了氯巴占、大麻二酚辅助治疗LGS。本文从氯巴占和大麻二酚的化学结构、药理作用、疗效、安全性、药物相互作用等方面进行综述,以介绍两种药物的研究现状和已有成果。LennoxGastaut syndrome(LGS)is a severe,epileptic encephalopathy.In recent years,a variety of drugs have been approved for the treatment of LGS.The U.S.Food and Drug Administration approved clobazam and cannabidiol as adjunctive therapy for LGS in October 2011 and June 2018,respectively.This article provides an overview of clobazam and cannabidiol,including their chemical structures,pharmacological actions,curative effects,safety profile,drug interactions,to introduce the current state of research and the achievements of both drugs.

关 键 词：罕见病 LENNOX-GASTAUT综合征 氯巴占 大麻二酚 孤儿药 

分 类 号：R742.1[医药卫生—神经病学与精神病学] R96[医药卫生—临床医学]